The FTC argues that pharmacy benefit managers have created a "perverse drug rebate system" that inflates insulin prices, leading to billions collected, while patients face rising costs.
The FTC noted that even when cheaper insulins became available, PBMs systematically favored high list-priced products, contributing to a drastic 600% increase over the past two decades.
Collection
[
|
...
]